Skip to main content
. 2019 Feb 8;11(2):197. doi: 10.3390/cancers11020197

Figure 1.

Figure 1

(A) Effect of varying concentrations of lapatinib on the growth of HER2 positive breast cancer cells. Cells were treated for 4 days and then counted using Viacount on the Guava system. The effect of lapatinib on the growth of cells was determined relative to untreated control cells (error bars reflect n = 3). (B) HCC1419 cells were treated twice weekly with 250 nM lapatinib for approx. 3 months. Images taken at 400× magnification. (C) HCC1419 cells were treated twice weekly with 50 µM bromodeoxyuridine (BrDU) for two weeks and fixed and stained for SA-β-gal activity and compared to untreated control cells (Images taken at 200×). (D) HCC1419, SKBR3 and EFM-192A cells were treated with 250 nM lapatinib, MDA-MB-361 cells were treated with 500 nM lapatinib and MDA-MB-453 cells and MCF7 cells as a negative control, were treated with 1 µM lapatinib, twice weekly for an extended period of time (ranging from 1–4 weeks). Cells were then fixed and stained for SA-β-gal activity and compared to untreated control cells. Images taken at 400× magnification. (E) HCC1419 cells were treated with a range of lapatinib concentrations twice a week for 1 week. Cells were then fixed and stained for SA-β-gal activity. Images taken at 400× magnification.